Get the Stockscreener App
7.13
2.46%
-0.18
Pre-market:
7.13
Silence Therapeutics Plc Adr stock is traded at $7.13, with a volume of 95,853.
It is down -2.46% in the last 24 hours and up +30.35% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$7.31
Open:
$7.33
24h Volume:
95,853
Relative Volume:
0.30
Market Cap:
$336.78M
Revenue:
$561.30K
Net Income/Loss:
$-88.91M
P/E Ratio:
-3.7877
EPS:
-1.8824
Net Cash Flow:
$-62.47M
1W Performance:
-7.40%
1M Performance:
+30.35%
6M Performance:
-0.42%
1Y Performance:
+77.81%
1-Day Range:
$7.0155
$7.33
1-Week Range:
$6.89
$8.01
52-Week Range:
$3.535
$8.40
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
7.13 | 336.78M | 561.30K | -88.91M | -62.47M | -1.8824 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
Book value per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 1.8%Here's What Happened - MarketBeat
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Urgent.ly Shares Are Trading Higher By Around 159%; Here Are 20 Stocks Moving Premarket - Benzinga
What is HC Wainwright's Estimate for SLN FY2030 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for SLN FY2030 Earnings? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics Q4 Earnings Assessment - Sahm
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High? - Yahoo Finance
Wall Street experts predict a potential 467.47% increase for Silence Therapeutics (SLN): Is such a surge in the stock truly possible? - Bitget
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1%Here's What Happened - MarketBeat
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - Sahm
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - Sahm
Silence Therapeutics ADR share price | SLN - Hargreaves Lansdown
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 - Investing.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7%Should You Sell? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell? - Defense World
Silence Therapeutics Insider Ups Holding During Year - Sahm
Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & Silence Therapeutics (NASDAQ:SLN) - Defense World
Was Autonomix Medical Inc (AMIX)’s session last reading good? - uspostnews.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors By Investing.com - Investing.com South Africa
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com
Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):